Optimization of prednisolone-loaded long-circulating liposomes via application of Quality by Design (QbD) approach

References

• Alupei MC, Licarete E, Cristian FB, Banciu M. (2014). Cytotoxicity of lipophilic statins depends on their combined actions on HIF-1α expression and redox status in B16.F10 melanoma cells. Anti-Cancer Drugs 25:393–405
   PubMed Web of Science ®Google Scholar
• Alupei MC, Licarete E, Patras L, Banciu M. (2015). Liposomal simvastatin inhibits tumor growth via targeting tumor-associated macrophages-mediated oxidative stress. Cancer Lett 356:946–52
   PubMed Web of Science ®Google Scholar
• Amasya G, Badilli U, Aksu B, Tarimci N. (2016). Quality by design case study 1: design of 5- fluorouracil loaded lipid nanoparticles by the W/O/W double emulsion- Solvent evaporation method. Eur J Pharm Sci 84:92–102
   PubMed Web of Science ®Google Scholar
• Andersen OS, Koeppe RE. II. (2007). Bilayer thickness and membrane protein function: an energetic perspective. Annu Rev Biophys Biomol Struct 36:107–30
   PubMedGoogle Scholar
• Banciu M, Fens MH, Storm G, Schiffelers RM. (2008a). Antitumor activity and tumor localization of liposomal glucocorticoids in B16 melanoma-bearing mice. J Control Release 127:131–6
   PubMed Web of Science ®Google Scholar
• Banciu M, Metselaar JM, Schiffelers RM, Storm G. (2008b). Liposomal glucocorticoids as tumor-targeted anti-angiogenic nanomedicine in B16 melanoma-bearing mice. J Steroid Biochem Mol Biol 111:101–10
   PubMed Web of Science ®Google Scholar
• Banciu M, Metselaar JM, Schiffelers RM, Storm G. (2008c). Antitumor activity of liposomal prednisolone phosphate depends on the presence of functional tumor-associated macrophages in tumor tissue. Neoplasia 10:108–17
   PubMed Web of Science ®Google Scholar
• Bradford M. (1976). A rapid and sensitive method for the quantification of microgram quantities of protein utilizing the principle of protein–dye binding. Anal Biochem 72:248–54
   PubMed Web of Science ®Google Scholar
• Calorini L, Bianchini F, Mannini A, et al. (2005). Enhancement of nitric oxide release in mouse inflammatory macrophages co-cultivated with tumor cells of a different origin. Clin Exp Metastasis 22:413–19
   PubMed Web of Science ®Google Scholar
• Davis ME, Chen ZG, Shin DM. (2008). Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat Rev Drug Discov 7:771–82
   PubMed Web of Science ®Google Scholar
• Drummond DC, Meyer O, Hong K, et al. (1999). Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharmacol Rev 51:691–743
   PubMed Web of Science ®Google Scholar
• Eon-Duval A, Valax P, Solacroup T, et al. (2012). Application of the Quality by Design approach to the drug substance manufacturing process of an Fc fusion protein: Towards a global multi-step design space. J Pharm Sci 101:3604–18
   PubMed Web of Science ®Google Scholar
• Gabizon AA. (2001). Stealth liposomes and tumor targeting: one step further in the quest for the magic bullet. Clin. Cancer Res 7:223–5
   PubMed Web of Science ®Google Scholar
• Glodek M, Liebowitz S, McCarthy R, et al. (2006). Process robustness: a PQRI white paper. Pharm Eng 26:1–11
   Google Scholar
• Guan T, Miao Y, Xu L, et al. (2011). Injectable nimodipine-loaded nanoliposomes: preparation, lyophilization and characteristics. Int J Pharm 410:180–7
   PubMed Web of Science ®Google Scholar
• ICH Q8 (R2). Pharmaceutical development. 2009. Available from: http://www.fda.gov/downloads/Drugs/Guidances/ucm073507.pdf
   Google Scholar
• ICH Q9. Quality risk management. 2005. Available from: http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q9/Step4/Q9_Guideline.pdf
   Google Scholar
• Kirby C, Clarke J, Gregoriadis G. (1980). Effect of the cholesterol content of small unilamellar liposomes on their stability in vivo and in vitro. Biochem J 186:591–8
   PubMed Web of Science ®Google Scholar
• Lee SC, Lee KE, Kim JJ, Lim SH. (2005). The effect of cholesterol in the liposome bilayer on the stabilization of incorporated Retinol. J Liposome Res 15:157–66
   PubMed Web of Science ®Google Scholar
• Liu D, Xu H, Tian B, et al. (2012). Fabrication of carvedilol nanosuspensions through the anti-solvent precipitation-ultrasonication method for the improvement of dissolution rate and oral bioavailability. AAPS PharmSciTech 13:295–304
   PubMed Web of Science ®Google Scholar
• Martinez FO, Gordon S, Locati M, Mantovani A. (2006). Transcriptional profiling of the human monocyte-to-macrophage differentiation and polarization: new molecules and patterns of gene expression. J Immunol 177:7303–11
   PubMed Web of Science ®Google Scholar
• Martinez FO, Helming L, Gordon S. (2009). Alternative activation of macrophages: an immunologic functional perspective. Annu Rev Immunol 27:451–83
   PubMed Web of Science ®Google Scholar
• Martinez FO, Gordon S. (2014). The M1 and M2 paradigm of macrophage activation: time for reassessment. F1000prime Reports [Online] 6:13. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3944738&tool=pmcentrez&rendertype=abstract [last accessed 27 Feb 2016]
   PubMedGoogle Scholar
• Mayer LD, Tai LC, Ko DS, et al. (1989). Influence of vesicle size, lipid composition, and drug-to-lipid ratio on the biological activity of liposomal doxorubicin in mice. Cancer Res 49:5922–30
   PubMed Web of Science ®Google Scholar
• Morel S, Ugazio E, Cavalli R, et al. (1996). Thymopentin in solid lipid nanoparticles. Int J Pharm 132:259–61
   Web of Science ®Google Scholar
• Pandey AP, Karande KP, Sonawane RO, Deshmukh PK. (2014). Applying quality by design (QbD) concept for fabrication of chitosan coated nanoliposomes. J Liposome Res 24:37–52
   PubMed Web of Science ®Google Scholar
• Porfire A, Tomuta I, Muntean D, et al. (2015). Optimizing long-circulating liposomes for delivery of simvastatin to C26 colon carcinoma cells. J Liposome Res 25:261–9
   PubMed Web of Science ®Google Scholar
• Rahman Z, Zidan AS, Habib MJ, Khan MA. (2010). Understanding the quality of protein loaded PLGA nanoparticles variability by Plackett-Burman design. Int J Pharm 389:186–94
   PubMed Web of Science ®Google Scholar
• Roy S. (2012). Quality by design: a holistic concept of building quality in pharmaceuticals. Int J Pharm Biomed Res 3:100–8
   Google Scholar
• Sangshetti JN, Deshpande M, Zaheer Z, et al. (2014). Quality by design approach: Regulatory need. Arab J Chem [Online] 101:1–14. Available from: http://dx.doi.org/10.1016/j.arabjc.2014.01.025 [last accessed 12 Jan 2016]
   Google Scholar
• Schiffelers RM, Metselaar JM, Fens MH, et al. (2005). Liposome-encapsulated prednisolone phosphate inhibits growth of established tumors in mice. Neoplasia 7:118–27
   PubMed Web of Science ®Google Scholar
• Schiffelers RM, Banciu M, Metselaar JM, Storm G. (2006). Therapeutic application of long-circulating liposomal glucocorticoids in auto-immune diseases and cancer. J Liposome Res 16:185–94
   PubMed Web of Science ®Google Scholar
• Shaji J, Lal M. (2013). Nanocarriers for targeting in inflammation. Asian J Pharm Clin Res 6:3–12
   Google Scholar
• Tefas LR, Muntean D-M, Vlase L, et al. (2014). Quercetin-loaded liposomes: formulation optimization through a D-optimal experimental design. Farmacia 63:26–33
   Web of Science ®Google Scholar
• Torchilin VP. (2000). Drug targeting. Eur J Pharm Sci. 11:81–91
   PubMed Web of Science ®Google Scholar
• Vemuri S, Rhodes CT. (1995). Preparation and characterization of liposomes as therapeutic delivery systems: a review. Pharmaceutica Acta Helvetiae 70:95–111
   PubMedGoogle Scholar
• Vogt NB. (1992). Quality by design managing research and development. Chemometr Intell Lab Syst 14:93–101
   Web of Science ®Google Scholar
• Xu X, Khan MA, Burgess DJ. (2011). A quality by design (QbD) case study on liposomes containing hydrophilic API: I. Formulation, processing design and risk assessment. Int J Pharm 419:52–9
   PubMed Web of Science ®Google Scholar
• Xu X, Costa AP, Khan MA, Burgess DJ. (2012a). Application of quality by design to formulation and processing of protein liposomes. Int J Pharm 434:349–59
   PubMed Web of Science ®Google Scholar
• Xu X, Khan MA, Burgess DJ. (2012b). A quality by design (QbD) case study on liposomes containing hydrophilic API: II. Screening of critical variables, and establishment of design space at laboratory scale. Int J Pharm 423:543–53
   PubMed Web of Science ®Google Scholar
• Xu X, Khan MA, Burgess DJ. (2012c). Predicting hydrophilic drug encapsulation inside unilamellar liposomes. Int J Pharm 423:410–18
   PubMed Web of Science ®Google Scholar
• Yu LX. (2008). Pharmaceutical quality by design: product and process development, understanding, and control. Pharm Res 25:781–91
   PubMed Web of Science ®Google Scholar